OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

September 9th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 9th 2020

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Woyach on Remaining Sequencing Questions in CLL

September 9th 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

September 9th 2020

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

September 9th 2020

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

September 9th 2020

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma

September 9th 2020

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Dr. Burris on Recent Advances in TNBC

September 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.

Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast Cancer

September 8th 2020

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma

September 8th 2020

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Dr. Chari on the FDA Approval of Belantamab Mafodotin in R/R Multiple Myeloma

September 8th 2020

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.

Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer

September 8th 2020

Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.

Dr. Konduri on Sequencing Challenges in ALK+ NSCLC

September 8th 2020

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Dr. McGregor on the Need to Develop Novel Targets in RCC

September 8th 2020

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Dr. Morris on the Design of the COBRA Trial in Stage II Colon Cancer

September 8th 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

September 5th 2020

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

September 3rd 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.